HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, H. Articles by Dear, A. E Search for Related Content PubMed PubMed Citation Articles by Liu, H. Articles by Dear, A. E

¹ Australian Centre for Blood Diseases and ² Eastern Clinical Research Unit, Biotechnology Division, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia ³ Department of Diabetes and Endocrinology, 4th Floor Clive Ward Centre, Box Hill Hospital, Arnold Street, Box Hill 3128, Melbourne, Victoria, Australia

(Correspondence should be addressed to A E Dear; Email: anthony.dear{at}med.monash.edu.au)

Glucagon-like peptide-1 (GLP-1) has been proposed as a target for treatment of type 2 diabetes. GLP-1 has also been demonstrated to improve endothelial cell dysfunction in diabetic patients. Elevated plasmogen activator inhibitor-1 (PAI-1) levels have been implicated in endothelial cell dysfunction. The effect of GLP-1 on PAI-1 expression in vascular endothelial cells has not been explored. In a spontaneously transformed human umbilical vein endothelial cell (HUVEC) line, C11-spontaneously transformed HUVEC (STH) and primary HUVEC cells, GLP-1 treatment, in the presence of a dipeptidyl peptidase IV inhibitor, attenuated induction of PAI-1 protein and mRNA expression by tumour necrosis factor- (TNF-). GLP-1 also inhibited the effect of TNF- on a reporter gene construct harbouring the proximal PAI-1 promoter. In addition, GLP-1 attenuated TNF--mediated induction of Nur77 mRNA and TNF--mediated binding of nuclear proteins (NPs) to the PAI-1, Nur77, cis-acting response element nerve growth factor induced clone B response element (NBRE). GLP-1 treatment also inhibited TNF--mediated induction of Akt phosphorylation. Taken together, these observations suggest that GLP-1 inhibits TNF--mediated PAI-1 induction in vascular endothelial cells, and this effect may involve Akt-mediated signalling events and the modulation of Nur77 expression and NP binding to the PAI-1 NBRE.

This article has been cited by other articles:

				B. Zinman, J. Gerich, J. B. Buse, A. Lewin, S. Schwartz, P. Raskin, P. M. Hale, M. Zdravkovic, L. Blonde, and the LEAD-4 Study Investigators Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) Diabetes Care, July 1, 2009; 32(7): 1224 - 1230. [Abstract] [Full Text] [PDF]

				H. Liu, A. E Dear, L. B Knudsen, and R. W Simpson A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules J. Endocrinol., April 1, 2009; 201(1): 59 - 66. [Abstract] [Full Text] [PDF]

				W. Kim and J. M. Egan The Role of Incretins in Glucose Homeostasis and Diabetes Treatment Pharmacol. Rev., December 1, 2008; 60(4): 470 - 512. [Abstract] [Full Text] [PDF]